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Summary  Dual  antiplatelet  therapy  with  aspirin  and  clopidogrel  is  routinely  used  to  pre-
vent thrombotic  events  in  patients  with  acute  coronary  syndrome  undergoing  percutaneous
coronary  intervention  (PCI)  in  Japan.  However,  these  agents  have  various  limitations  and  some
patients will  experience  further  cardiovascular  events.  The  purpose  of  this  article  is  to  review
the antiplatelet  agents  currently  used  in  patients  undergoing  PCI  in  Japan,  to  discuss  the  issuesDrug  therapy;
Adenosine
diphosphate
and limitations  associated  with  these  antiplatelet  agents,  and  to  characterize  new  antiplatelet
agents currently  under  investigation  in  Japan.  Particular  emphasis  is  placed  on  the  novel
thienopyridine  prasugrel,  and  the  potential  this  drug  has  for  overcoming  the  issues  associated
with other  antiplatelet  agents.
© 2011  Japanese  College  of  Cardiology.  Published  by  Elsevier  Ltd.  All  rights  reserved.
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When  ruptured,  coronary  artery  plaques  release  thrombo-
genic  substances  into  the  circulation,  stimulating  platelet
activation  and  aggregation  [1].  Patients  undergoing  percu-
taneous  coronary  intervention  (PCI)  are  at  particular  risk  of
thrombotic  events,  particularly  when  stents  are  placed.  PCI
is  conducted  in  approximately  two-thirds  of  patients  with
myocardial  infarction  (MI)  in  Japan,  and  is  much  more  fre-
quently  performed  in  Japan  than  in  the  USA  or  Europe  [2].
Antiplatelet  agents  play  a  key  role  in  preventing  throm-
bosis  in  patients  undergoing  PCI  [3].  The  Clopidogrel  in
Unstable  Angina  to  Prevent  Recurrent  Events  (CURE)  Trial
[4]  showed  a  greater  reduction  in  stent  thrombosis  follow-
ing  treatment  with  aspirin  in  combination  with  clopidogrel
as  compared  with  aspirin  alone.  Therefore,  dual  antiplatelet
therapy  is  now  the  standard  of  care  for  the  prevention
of  ischemic  events  in  such  patients  [1,3]. However,  some
patients  remain  at  increased  risk  of  ischemic  events  follow-
ing  successful  PCI  and  treatment  with  the  currently  available
antiplatelet  agents  [1,3].
This  article  reviews  the  antiplatelet  agents  currently
used  to  prevent  thrombosis  in  patients  undergoing  PCI,  the
issues  associated  with  such  agents,  and  the  characteris-
tics  of  the  novel  antiplatelet  agent  prasugrel,  including  the
potential  that  this  agent  may  have  in  overcoming  the  issues
associated  with  other  agents.  Furthermore,  we  discuss  the
current  situation  in  Japan,  and  steps  being  taken  to  over-
come  the  limitations  associated  with  current  therapies  for
Japanese  patients.
ADP receptor inhibitors
Adenosine  diphosphate  (ADP),  a  nucleotide  found  in
platelets,  is  the  product  of  adenosine  triphosphate  (ATP)
dephosphorylation.  ADP  binds  to  purinergic  receptors  (prin-
cipally  P2Y1 and  P2Y12)  expressed  on  the  platelet  membrane
to  mediate  platelet  activation  and  aggregation  (reviewed
by  Angiolillo  et  al.  [5]).  The  P2Y1 receptor  is  a  G/q11-
coupled  G-protein  receptor  that  plays  an  important  role
in  responses  to  shear  stress  by  mobilizing  intracellular  cal-
cium  [6].  The  P2Y12 receptor  is  a  Gi-coupled  G-protein
receptor  that  plays  similar  roles  to  P2Y1,  but  is  also  impor-
tant  in  the  potentiation  of  platelet  activation  mediated
by  physiological  agonists,  such  as  collagen,  von  Willebrand
factor  and  thromboxane  A2,  and  is  essential  for  aggrega-
tion  [6—8]. Activation  of  P2Y12 reduces  adenylyl  cyclase
activity,  which  ultimately  leads  to  platelet  aggregation
d
a
mnd  ﬁbrinogen-mediated  platelet  crosslinking  [9].  Clopido-
rel  and  ticlopidine  are  thienopyridines  that  preferentially
nhibit  the  P2Y12 receptor  and  prevent  ADP-mediated  inhi-
ition  of  adenylyl  cyclase  activity,  thus  reducing  platelet
ggregation  [7,8,10].
iclopidine
iclopidine  is  a  ﬁrst-generation  thienopyridine  that,  in
apan,  is  used  after  PCI  for  the  ‘‘treatment  of  thrombosis
nd  embolism  in  association  with  vascular  surgery  and  blood
irculation  outside  the  body  as  well  as  the  improvement  of
lood  circulation  disorders’’  [11].
In  early  clinical  studies,  ticlopidine  alone  or  in  combina-
ion  with  aspirin  was  shown  to  be  more  effective  than  other
nticoagulants  in  preventing  stent  thrombosis  after  coronary
rtery  stenting  [12,13],  and  more  effective  than  aspirin  [14]
r  a  placebo  [15]  in  the  prevention  of  recurrent  stroke  in
atients  who  had  recently  experienced  a  thromboembolic
troke  [15], or  an  episode  of  transient  or  mild  persistent
ocal  cerebral  or  retinal  ischemia  [14]. Ticlopidine  was  also
ore  effective  than  a  placebo  in  reducing  the  incidence  of
ascular  surgery  in  patients  with  intermittent  claudication
16].
However,  ticlopidine  is  associated  with  a  risk  of
otentially  life-threatening  hematologic  adverse  events
e.g.  neutropenia/agranulocytosis,  thrombotic  thrombocy-
openic  purpura,  and  aplastic  anemia).  In  addition  to  the
ess  favorable  safety  proﬁle  of  ticlopidine  compared  with
lopidogrel  or  prasugrel,  ticlopidine  also  has  a  slower  onset
f  action  than  prasugrel,  but  one  that  is  similar  to  that  of
lopidogrel  (reviewed  by  Angiolillo  [3]).  As  a consequence
f  these  limitations,  ticlopidine  is  used  less  frequently  than
lopidogrel  in  many  countries  [3].  Nevertheless,  ticlopidine
s  still  widely  used  in  Japan  partly  because  of  the  more
imited  indication  for  clopidogrel.
lopidogrel
n  Japan,  clopidogrel,  a  second-generation  thienopyridine,
s  approved  for  use  in  patients  with  acute  coronary  syndrome
ACS)  [either  non-ST-elevation  myocardial  infarction  (STEMI)
r  unstable  angina]  undergoing  PCI,  and  for  the  prevention
f  recurrent  ischemic  cerebrovascular  disorder  (except  car-
ioembolic  stroke)  [17].
In  large  (n  =  3491—45,852),  randomized,  double-blind  tri-
ls,  clopidogrel  alone  or  in  combination  with  aspirin  was
ore  effective  than  aspirin  alone  in  reducing  major  cardio-
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ascular  events  in  patients  with  recent  non-STEMI,  STEMI,
troke,  or  symptomatic  peripheral  artery  disease  [18]; in
ecreasing  the  incidence  of  death,  reinfarction,  or  stroke
n  post-STEMI  patients  [19]; and  in  reducing  the  risk  of  an
ccluded  infarct-related  artery  on  angiography,  death,  or
ecurrent  MI  before  angiography  in  acute  STEMI  patients
cheduled  to  undergo  angiography  [20].
In  addition,  in  two  [21,22]  of  three  [21—23]  studies
omparing  clopidogrel  with  ticlopidine,  clopidogrel  plus
spirin  demonstrated  a  more  favorable  tolerability/safety
roﬁle  than  ticlopidine  plus  aspirin  in  patients  undergo-
ng  coronary  stent  placement.  In  the  third  study  [23], the
wo  drugs  appeared  to  have  similar  tolerability  proﬁles,
lthough  clopidogrel  was  associated  with  fewer  non-cardiac
vents  than  ticlopidine.  Furthermore,  in  an  analysis  of  two
apanese  studies  conducted  in  patients  with  prior  stroke,
he  safety  proﬁle  of  clopidogrel  was  signiﬁcantly  better  than
hat  of  ticlopidine  [24]. In  all  of  these  studies,  the  two  drugs
ad  a  similar  efﬁcacy  with  regard  to  prevention  of  cardio-
ascular  events.
Based  on  the  results  of  large  trials,  clopidogrel  has
ecome  the  antiplatelet  agent  of  choice  to  prevent  throm-
otic  events  [3].  Current  US-based  guidelines  recommend
ntiplatelet  therapy  with  a  combination  of  aspirin  and  clopi-
ogrel  for  patients  who  are  undergoing  PCI  or  who  have  ACS
25,26].  Although  Japanese  guidelines  state  that  ticlopidine
lus  aspirin  is  the  antiplatelet  regimen  of  choice  in  patients
ndergoing  coronary  artery  stenting,  ticlopidine  is  expected
o  be  replaced  by  clopidogrel  because  of  the  more  favorable
olerability  proﬁle  associated  with  the  latter  drug  [27]. How-
ver,  clopidogrel  has  limitations  that  should  be  discussed.
ssues associated with clopidogrel
lopidogrel  is  an  inactive  prodrug  that  is  converted  into
ts  active  form  via  hepatic  cytochrome-mediated  biotrans-
ormation  in  the  liver  (reviewed  by  Angiolillo  et  al.  [1]).
ctivation  of  clopidogrel  is  inefﬁcient,  with  as  little  as
0—15%  of  the  prodrug  becoming  active  and  the  remainder
eing  hydrolyzed  into  an  inactive  form  [28]. Clopidogrel  also
as  a  slow  onset  of  action,  reaching  steady-state  in  3—7
ays  at  a  dose  of  75  mg  [29]. However,  this  can  be  short-
ned  by  the  administration  of  a  loading  dose  (300—600  mg),
hich  can  reduce  the  time  to  reach  inhibitory  levels  close
o  steady-state  to  approximately  2  h  [29]. Clopidogrel  is  also
ssociated  with  a  delayed  cessation  of  action,  which  may  be
roblematic  in  patients  requiring  CABG  or  other  surgery.  In
ddition,  the  patient  responses  to  clopidogrel  show  great
nter-individual  variability  [30]. Furthermore,  the  drug  has
een  associated  with  incomplete  platelet  inhibition  or  poor
esponsiveness  [1,10].
oor  responsiveness  to  clopidogrel
oor  response  to  clopidogrel  may  be  divided  into  the
ollowing  categories:  clinical  response  (occurrence  of  car-
iovascular  events  while  taking  antiplatelet  agents)  and
aboratory  response  (incomplete  blocking  of  platelet  activ-
ty  in  vitro) [31]. However,  the  poor  response  determined
y  laboratory  tests  of  platelet  function  shows  low  sensitivity
nd  speciﬁcity  for  identifying  thrombotic  risk  [31].
(
p
t
*H.  Ogawa  et  al.
The frequency  of  poor  response  to  clopidogrel  varies
reatly  because  of  differences  in  a  variety  of  factors,
uch  as  the  deﬁnition  of  response  used,  the  laboratory
est  employed,  the  patient  population  studied,  and  the
rug  dosing  regimen  administered  (reviewed  by  Kuliczkowski
t  al.  [32]). For  example,  when  platelet  aggregation
nduced  by  ADP  was  assessed  by  optical  transmittance,
oor  response  ranged  from  5  to  44%;  in  a  meta-analysis,
ncomplete  inhibition  of  platelets  was  seen  in  about  21%  of
atients  undergoing  PCI;  and  using  cytometric  analysis  with
asodilator-stimulated  phosphoprotein  (VASP),  the  preva-
ence  was  around  30%  [32]. Poor  response  to  clopidogrel  has
lso  been  reported  in  several  studies  in  Japan,  with  approxi-
ately  14%  of  patients  undergoing  PCI  being  non-responders
o  clopidogrel  [33].
The  causes  of  poor  responsiveness  to  clopidogrel  are
ikely  multifactorial  and  may  be  divided  into  genetic,  clin-
cal,  and  cellular  factors  (Fig.  1)  (reviewed  by  Angiolillo
t  al.  [1]  and  Sweeny  et  al.  [34]). Examples  of  contributing
actors  include:  poor  drug  compliance/underdosing;  poor
rug  bioavailability/absorption;  the  inﬂuence  of  metabo-
izing  enzyme  cytochrome  P450  subtypes;  the  inﬂuence  of
YP2C19  genetic  variants;  and  possible  drug-to-drug  inter-
ctions  with  other  commonly  used  medications,  such  as
tatins  and  proton  pump  inhibitors  [1,34].
CYP2C19  is  an  important  enzyme  involved  in  the  altered
harmacokinetic  proﬁles  of  a  number  of  drugs  [35]. On
he  basis  of  their  ability  to  metabolize  various  CYP2C19
ubstrates,  patients  can  be  classiﬁed  as  extensive,  inter-
ediate,  or  poor  metabolizers  [35]. More  Asians  than
aucasians  (12—23%  vs.  1—6%)  carry  genetic  polymorphisms
ausing  them  to  be  poor  metabolizers  of  CYP2C19  substrates
35].  A  signiﬁcantly  higher  incidence  of  cardiovascular
dverse  events  was  reported  after  acute  MI  in  clopidogrel-
reated  patients  with  CYP2C19  loss-of-function  alleles  than
n  those  with  functional  alleles  [36]. In  addition,  the
YP2C19*2  genetic  variant  was  a  major  determinant  of  prog-
osis  in  young  patients  treated  with  clopidogrel  after  MI
37]. Furthermore,  among  persons  treated  with  clopidogrel,
arriers  of  a  reduced-function  CYP2C19  allele  had  signiﬁ-
antly  lower  levels  of  the  active  metabolite  of  clopidogrel,
iminished  platelet  inhibition,  and  a  higher  rate  of  major
dverse  cardiovascular  events,  including  stent  thrombosis,
han  did  non-carriers  [38]. In  contrast,  in  patients  with  ACS
r  atrial  ﬁbrillation,  clopidogrel  was  more  effective  than
lacebo  in  reducing  the  rate  of  cardiovascular  events,  irre-
pective  of  CYP2C19  loss-of-function  allele  status;  however,
atients  carrying  CYP2C19  gain-of-function  alleles  appeared
o  beneﬁt  more  from  clopidogrel  than  did  non-carriers  [39].
The  prevalence  of  polymorphisms  in  CYP2C19  is  relatively
igh  in  Japanese  patients  [40], and  these  polymorphisms
ere  shown  to  have  marked  effects  on  the  response  to
lopidogrel.  Indeed,  we  recently  reported  the  impact  of
he  CYP2C19  genotype  on  platelet  activity  in  201  Japanese
atients  with  stable  coronary  heart  disease  (CHD)  during
ntiplatelet  therapy.  In  these  patients,  the  distribution  of
he  CYP2C19*1/*1,  *1/*2,  *1/*3,  *2/*2,  *2/*3  and  *3/*3  geno-
ypes  was  37%,  33%,  11%,  11%,  7%,  and  1%,  respectively
Fig.  2).  Among  those  treated  with  dual  antiplatelet  therapy,
latelet  reactivity  was  most  signiﬁcantly  decreased  in  wild-
ype  homozygotes  (CYP2C19*1/*1),  followed  by  the  *2  and
3  heterozygotes  (*1/*2,  *1/*3),  but  was  poorly  inhibited  in
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cFigure  1  Variability  in  the  response  to  clopid
*2/*2,  *2/*3,  and  *3/*3  individuals.  However,  when  patients
carrying  the  variant  allele  were  classiﬁed  into  two  groups
based  on  the  duration  of  dual  antiplatelet  therapy,  platelet
reactivity  was  signiﬁcantly  decreased  in  those  treated  for
>7  days  compared  with  those  treated  for  <7  days  (Fig.  3).
Moreover,  the  incidence  of  cardiovascular  events  was  higher
in  patients  carrying  at  least  one  variant  allele  than  in  wild-
type  homozygotes  [41]. In  that  study,  we  also  investigated
the  relationship  between  CYP2C19  polymorphisms  and  car-
diovascular  events  in  98  patients.  As  shown  in  Fig.  4,  the
prevalence  of  subsequent  cardiovascular  events  was  sig-
niﬁcantly  higher  in  carriers  than  in  non-carriers,  despite
treatment  with  clopidogrel.
Poor  metabolism  of  clopidogrel  in  some  patients  has
resulted  in  the  addition  of  a  ‘boxed  warning’  by  the  US
Food  and  Drug  Administration  [42]. This  warns  clinicians
of  the  possibility  of  reduced  effectiveness  in  patients  who
are  poor  metabolizers  of  clopidogrel.  Increasing  the  dosage
of  clopidogrel  might  be  expected  to  overcome  poor  clini-
cal  response.  However,  this  is  not  uniformly  supported  by
a
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Figure  2  Distribution  of  CYP2C19  phenotypes  and  genotypes  in  
antiplatelet therapy  [41].  EM,  extensive  metabolizers;  IM,  interm
permission from  Elsevier.l  [1]. Reprinted  with  permission  from  Elsevier.
esults  of  clinical  trials  indicating  that  targeting  an  inde-
endent  pathway  may  offer  a  more  effective  approach  than
ttempting  to  overload  an  ineffective  system  [43].
Three-hydroxy-3-methylglutaryl-coenzyme  A  (HMG  CoA)
eductase  inhibitors  (statins)  are  widely  used  among
atients  with  cardiovascular  disease.  Several  studies  have
uggested  that  some  statins,  including  simvastatin  and  ﬂu-
astatin,  may  reduce  the  bioactivity  of  clopidogrel,  although
his  was  not  a  class  effect,  and  other  studies  showed  no
ffect  of  concomitant  statin  use  on  clopidogrel  [44]. Never-
heless,  clinicians  should  be  aware  of  possible  interactions
etween  these  drugs.
Proton  pump  inhibitors  (PPI)  are  often  needed  in  patients
iven  antithrombotic  agents  because  of  the  increased  risk
f  gastrointestinal  bleeding  [37,45,46]. Concomitant  use  of
lopidogrel  and  PPI  after  hospital  discharge  for  ACS  was
ssociated  with  an  increased  risk  of  adverse  outcomes  com-
ared  with  the  use  of  clopidogrel  without  PPI,  suggesting
hat  the  use  of  PPI  may  be  associated  with  an  attenuation
f  the  beneﬁts  of  clopidogrel  after  ACS  [47—49]. How-
201  Japanese  patients  with  stable  coronary  heart  disease  on
ediate  metabolizers;  PM,  poor  metabolizers.  Reprinted  with
10  H.  Ogawa  et  al.
Figure  3  (A)  On-treatment  platelet  reactivity  according  to  time  between  clopidogrel  loading  and  platelet  function  test  among
e  [41]
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ctive metabolites  of  prasugrel  and  clopidogrel  following  a  load
etabolizers  (RM)  [62].  Reprinted  with  permission  from  the  Eur
ver,  these  ﬁndings  are  equivocal,  as  a  sub-analysis  [50]  of
RITON-TIMI  38  (Trial  to  Assess  Improvement  in  Therapeutic
utcomes  by  Optimizing  Platelet  Inhibition  with  Prasugrel-
hrombolysis  in  Myocardial  Infarction)  found  no  association
etween  PPI  use  and  the  primary  endpoint  (composite  of
ardiovascular  death,  MI,  or  stroke)  in  patients  treated  with
lopidogrel  [hazard  ratio  (HR)  =  0.94;  95%  conﬁdence  inter-
al  (CI)  =  0.80—1.11].
vercoming poor responsiveness to
lopidogrellthough  there  are  no  formal  recommendations  for
‘treating’’  incomplete  responses,  a  number  of  approaches
ave  been  proposed  (reviewed  by  Kuliczkowski  et  al.  [32]).
hese  include  the  use  of  glycoprotein  IIb/IIIa  during  elec-
T
c
d. Reprinted  with  permission  from  Elsevier.  (B)  Exposure  to  the
ose  of  60  mg  prasugrel  or  600  mg  clopidogrel  in  EM  and  reduced
n  Society  of  Cardiology/Oxford  University  Press.
ive angioplasty  [51,52];  increasing  the  clopidogrel  dose,
articularly  in  patients  with  diabetes  [53]; adding  in  a  third
ntiplatelet  drug  (e.g.  cilostazol)  [54,55]; switching  to  ticlo-
idine  [56]; and  switching  to  one  of  the  newer  antiplatelet
gents,  such  as  prasugrel  or  ticagrelor  [57].
In  the  next  section,  we  wish  to  focus  on  the  opportuni-
ies  provided  by  newer  antiplatelet  agents  and  the  possible
mplications  for  the  treatment  and  prevention  of  thrombosis
n  Japan.
DP receptor inhibitors in development in
apano  date,  much  of  our  knowledge  regarding  the  prevention  of
ardiovascular  disease  has  been  derived  from  studies  con-
ucted  largely  in  European  populations  [2,58]. Moreover,
Antiplatelet  therapy  in  PCI  
Figure  4  Kaplan—Meier  analysis  of  the  occurrence  of  cardio-
vascular  events  in  patients  treated  with  clopidogrel  (A)  [41].
Reprinted  with  permission  from  Elsevier.  A  composite  of  car-
diovascular  death  (CVD),  myocardial  infarction  (MI),  or  stroke
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din patients  treated  with  prasugrel  (B)  [63].  Reprinted  with  per-
mission from  Wolters  Kluwer.
Japanese  cardiovascular  prevention  guidelines  are  based
on  results  of  such  studies  [58]. However,  because  geo-
graphic  differences  in  cardiovascular  risk  factors  have  been
reported,  particularly  in  Asian  countries,  it  is  important  that
large,  well-designed  clinical  trials  are  conducted  in  these
countries  so  that  evidence-based  guidelines  speciﬁc  to  Asian
populations  can  be  prepared  [2,58]. The  following  sections
discuss  two  of  the  drugs  for  which  these  studies  are  being
performed,  with  particular  focus  on  prasugrel.
PrasugrelPrasugrel  is  a  third-generation  thienopyridine  that  is  indi-
cated  for  the  prevention  of  thrombotic  cardiovascular
events  in  patients  with  ACS  (unstable  angina,  non-STEMI,
or  STEMI)  who  are  to  be  managed  with  PCI  [59]. Com-
a
a
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ared  with  clopidogrel,  this  drug  has  a  faster  onset  of
ction,  greater  inhibition  of  platelet  aggregation  at  clinical
oses,  less  between-patient  variability,  and  a  more  efﬁcient
etabolism  (i.e.  more  efﬁcient  absorption  and  conversion  to
he  active  metabolite)  (reviewed  by  Angiolillo  [3]).
In  addition,  prasugrel  appears  to  be  effective  in  clopi-
ogrel  poor  responders  and  in  CYP2C19  genetic  variant
arriers.  For  example,  Brandt  et  al.  [60]  conducted  a  ran-
omized  crossover  trial  of  healthy  volunteers  to  compare  the
ffects  of  60  mg  prasugrel  and  300  mg  clopidogrel  on  platelet
ggregation  in  response  to  ADP.  They  found  that  inhibition  of
latelet  aggregation  in  response  to  5  and  20  mol/L  ADP  was
igniﬁcantly  greater  after  prasugrel  than  after  clopidogrel
5  mol/L  ADP:  84.1  ±  9.5%  vs.  48.9  ±  27.0%,  respectively;
0  mol/L  ADP:  78.8  ±  9.2%  vs.  35.0  ±  24.5%,  respectively;
oth,  p  <  0.001).  Prasugrel  was  also  effective  in  subjects
ith  poor  responsiveness  to  clopidogrel  (Fig.  5),  which  was
eﬁned  as  inhibition  of  platelet  aggregation  of  <25%  at  4  h
nd  24  h.  Similarly,  in  stable  aspirin-treated  patients  with
table  coronary  artery  disease,  Jernberg  et  al.  [61]  reported
hat  prasugrel  achieved  greater  inhibition  of  platelet  aggre-
ation  than  clopidogrel.  Moreover,  even  though  variation  in
he  gene  encoding  CYP2C19  contributed  to  reduced  expo-
ure  to  clopidogrel’s  active  metabolite  and  a  corresponding
eduction  in  P2Y(12)  inhibition  in  patients  with  stable  CHD,  it
id  not  signiﬁcantly  inﬂuence  the  response  to  prasugrel  [62].
imilarly,  common  functional  CYP  genetic  variants  did  not
ffect  active  drug  metabolite  levels,  inhibition  of  platelet
ggregation,  or  clinical  cardiovascular  event  rates  in  persons
reated  with  prasugrel.  Overall,  the  pharmacokinetic  and
harmacodynamic  characteristics  of  prasugrel  are  indepen-
ent  of  CYP2C19  status,  which  is  in  contrast  to  observations
ith  clopidogrel,  and  this  may  partly  explain  the  different
harmacological  and  clinical  responses  to  the  two  medica-
ions  [63]  (Figs.  3  and  4).
However,  because  of  its  mechanism  of  action,  prasugrel
as  the  same  limitations  as  clopidogrel  when  used  preoper-
tively,  including  the  risk  of  major  bleeding.  To  determine
ays  to  maximize  the  clinical  beneﬁts  of  prasugrel  and  to
imit  bleeding  and  risk,  future  studies  should  investigate
ndividualized  antiplatelet  therapy  regimens  based  on  point-
f-care  platelet  function  tests  [64]. This  would  be  similar  to
he  situation  for  patients  receiving  warfarin  who  undergo
onitoring  of  prothrombin  times.
The  efﬁcacy  of  prasugrel  in  preventing  major  cardio-
ascular  events  in  patients  with  ACS  undergoing  PCI  was
nvestigated  in  the  large  (n  =  13,608),  double-blind,  double-
ummy,  multicenter,  TRITON-TIMI  38  study  [57]. Patients  in
his  study  were  randomized  to  receive  prasugrel  (60  mg  load-
ng  dose,  then  10  mg/day)  or  clopidogrel  (300  mg  loading
ose,  then  75  mg/day)  for  up  to  15  months.  The  primary
omposite  endpoint  was  the  combined  incidence  of  cardio-
ascular  death,  nonfatal  MI,  and  nonfatal  stroke.
In  TRITON-TIMI  38,  the  incidence  of  cardiovascular  events
fter  stent  implantation  was  19%  lower  in  the  group
eceiving  prasugrel  once  daily  than  in  the  group  receiving
lopidogrel  once  daily  (Table  1)  [57]. In  addition,  the  inci-
ence  of  post-stent  thrombosis  in  the  prasugrel  group  was
bout  one-half  of  that  in  the  clopidogrel  group  (Table  1).  The
dvantages  of  prasugrel  over  clopidogrel  were  seen  early
nd  later  on  in  the  trial  [65], and  did  not  differ  with  stent
ype  (i.e.  drug-eluting  or  bare  metal)  [66]. In addition,  a
12  H.  Ogawa  et  al.
Figure  5  Inhibition  of  platelet  aggregation  (IPA)  with  clopidogrel  (300  mg)  and  prasugrel  (60  mg)  in  response  to  20  mol/L  ADP
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tt 24  h  after  the  loading  dose  [60].  Healthy  volunteers  (n  =  68)
el →  clopidogrel  or  clopidogrel  →  prasugrel)  with  a  2-week  wa
4 h.  Reprinted  with  permission  from  Elsevier.
ub-analysis  of  the  study  results  showed  that  PPI  use  was  not
ssociated  with  the  risk  of  the  primary  endpoint  in  patients
reated  with  either  agent  [50].
In terms  of  safety,  among  patients  with  STEMI  who  had
ndergone  coronary  artery  bypass  grafting  (CABG),  the  inci-
ence  of  thrombolysis  in  myocardial  infarction  (TIMI)  major
c
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Table  1  Efﬁcacy  of  prasugrel  in  patients  with  acute  coronary  synd
of the  large,  double-blind,  double-dummy,  multicenter  TRITON-T
prasugrel or  clopidogrel  for  up  to  15  months  [57].
Major  efﬁcacy  endpoints  in  the
overall  cohort  at  15  months
n  (%)  
Prasugrel  (N  =  6813)
Death  from  cardiovascular  causes,
nonfatal  MI,  or  nonfatal  stroke
(primary  endpoint)
643  (9.9)  
Death  from  cardiovascular  causes  133  (2.1)  
Nonfatal MI 475  (7.3)  
Nonfatal  stroke  61  (1.0)  
Death from  any  cause 188  (3.0)  
Death from  cardiovascular  causes,
nonfatal  MI,  or  urgent  target-vessel
revascularization
652 (10.0)  
Death  from  any  cause,  nonfatal  MI,  or
nonfatal  stroke
692  (10.7)  
Urgent  target-vessel
revascularization
156  (2.5)  
Death  from  cardiovascular  causes,
nonfatal  MI,  nonfatal  stroke,  or
rehospitalization  for  ischemia
797  (12.3)  
Stent  thrombosis‡ 68  (1.1)  
Reprinted from [57], with permission from the Massachusetts Medical S
* p < 0.001.
‡ Stent thrombosis was deﬁned as deﬁnite or probable thrombosis, a
patients at risk were all patients whose index procedure included at 
treatment groups.ived  clopidogrel  and  prasugrel  in  a  crossover  manner  (prasug-
 between  each  treatment.  *Poor  responder  =  IPA  <25%  at  4  and
r  minor  bleeding  was  signiﬁcantly  (p  =  0.0032)  higher  in
hose  who  received  prasugrel  than  in  those  who  received
lopidogrel  (Table  2)  [67], while  the  incidence  of  major
afety  endpoints,  including  TIMI  major  bleeding  in  non-CABG
atients  and  fatal  TIMI  major  bleeding  in  non-CABG  patients,
as  similar  in  both  groups  (Table  2)  [67]. In  contrast,  the
rome  undergoing  percutaneous  coronary  intervention.  Results
IMI  38  trial  in  which  patients  were  randomized  to  receive
Hazard  ratio  for
prasugrel  (95%  CI)
Clopidogrel  (N  =  6795)
781  (12.1)  0.81  (0.73—0.90)*
150  (2.4)  0.89  (0.70—1.12)
620  (9.5)  0.76  (0.67—0.85)*
60  (1.0)  1.02  (0.71—1.45)
197  (3.2)  0.95  (0.78—1.16)
798  (12.3)  0.81  (0.73—0.89)*
822  (12.7)  0.83  (0.75—0.92)*
233  (3.7)  0.66  (0.54—0.81)*
938  (14.6)  0.84  (0.76—0.92)*
142  (2.4)  0.48  (0.36—0.64)*
ociety. MI, myocardial infarction.
ccording to the Academic Research Consortium; the numbers of
least one intracoronary stent: 6422 patients in each of the two
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Table  2  Safety  of  prasugrel  in  patients  with  STEMI  undergoing  percutaneous  coronary  intervention.  Results  of  the  large,  double-
blind, double-dummy,  multicenter  TRITON-TIMI  38  trial  in  which  patients  were  randomized  to  receive  prasugrel  or  clopidogrel
for up  to  15  months  [67].
Safety  endpoint  at  15  months
No.  of  events  (%)
Treatment  group  Hazard  ratio  (95%  CI)
Prasugrel  Clopidogrel
TIMI  major  bleeding
(non-CABG-related)
38  (2.4)  34  (2.1)  1.11  (0.70—1.77)
TIMI life-threatening  bleeding  20  (1.3)  18  (1.1)  1.11  (0.59—2.10)
Fatal TIMI  major  bleeding
(non-CABG-related)
7  (0.45)  2  (0.13)  3.48  (0.72—16.75)
TIMI major  or  minor  bleeding
(non-CABG-related)
83 (5.1)  77 (4.7)  1.07  (0.79—1.47)
TIMI major  bleeding
(CABG-related)a
12  (18.8)  2  (2.7)  8.19  (1.76—38.18)b,*
TIMI  major  or  minor  bleeding
(CABG-related)a
14 (21.9)  3  (4.1)  6.53  (1.78—23.94)b,**
TIMI  major  or  minor  bleeding
(non-CABG-  or  CABG-related)
96 (5.9)  80 (4.8)  1.20  (0.89—1.61)
Reprinted from [67], with permission from Elsevier.
STEMI, ST-segment elevation myocardial infarction; CI, conﬁdence interval; TIMI, thrombolysis in myocardial infarction; CABG, coronary
artery bypass graft.
a 64 patients in the prasugrel group and 73 patients in the clopidogrel group underwent CABG, and analyses for this endpoint were
conducted only in this group of patients.
b Odds ratio.
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B* p = 0.0033 vs. prasugrel.
** p = 0.0032.
incidence  of  cardiovascular  death  or  non-fatal  myocardial
infarction  was  signiﬁcantly  lower  with  prasugrel  than  with
clopidogrel  [67]. A  subsequent  analysis  of  the  TRITON-TIMI
38  study  results  showed  that  the  mortality  rate  was  signif-
icantly  lower  in  patients  undergoing  isolated  CABG  treated
with  prasugrel  than  in  patients  treated  with  clopidogrel,
despite  the  higher  incidence  of  bleeding  with  prasugrel
[68].
In  the  TRITON-TIMI  38  study,  which  was  performed
predominantly  in  Caucasian  patients,  prasugrel  was  also
signiﬁcantly  more  effective  than  clopidogrel  in  terms  of
the  net  clinical-beneﬁt  endpoints  of  death,  MI,  stroke,  and
TIMI  major  bleeding  unrelated  to  CABG  (12.2%  vs.  14.6%;
p  =  0.0218),  and  death,  MI,  stroke,  and  TIMI  major  bleed-
ing  either  related  or  unrelated  to  CABG  (12.5%  vs.  14.7%;
p  =  0.0412)  [67].
The  pharmacokinetic  and  pharmacodynamic  characteris-
tics  of  prasugrel  have  been  assessed  in  Chinese,  Japanese,
and  Korean  subjects,  as  compared  with  white  volunteers
[69,70].  In  the  ﬁrst  study  [69], platelet  inhibition  was  sig-
niﬁcantly  higher  in  Chinese  than  in  white  volunteers  up  to
2  h  after  a  single  30-mg  dose  of  prasugrel,  and  at  all  times
after  a  30-mg  dose  of  prasugrel  than  after  a  300-mg  dose
of  clopidogrel.  In  the  second  study  [70], mean  exposure
to  the  active  metabolite  of  prasugrel  after  a  60-mg  load-
ing  dose  and  with  10-mg  or  5-mg  maintenance  doses  was
higher  in  Chinese,  Japanese,  and  Korean  volunteers  than
in  Caucasian  volunteers,  resulting  in  greater  platelet  inhi-
bition.  Taken  together,  these  results  suggest  that  prasugrel
may  be  as  effective  as  clopidogrel  in  Asian  patients  after
appropriate  dose  adjustments.  Longer  randomized  studies
h
T
[
tre now  needed  to  conﬁrm  the  clinical  efﬁcacy  and  safety
f  prasugrel  in  Japanese  and  other  Asian  patients.
icagrelor
icagrelor  is  a  reversible  ADP  receptor  antagonist  that  was
ecently  approved  in  the  EU  for  the  prevention  of  major  car-
iovascular  events  in  patients  with  ACS.  In  the  pivotal  PLATO
PLATelet  inhibition  and  patient  Outcomes)  study  [71], the
roup  receiving  ticagrelor  twice  daily  showed  a  16%  decrease
n  the  cardiovascular  composite  endpoint  compared  with
he  group  receiving  clopidogrel  once  daily.  Although  there
as  no  increase  in  the  incidence  of  CABG-related  major
leeding,  the  incidence  of  non-CABG-related  major  bleed-
ng  was  signiﬁcantly  higher  in  the  ticagrelor  groups,  as  was
he  incidence  of  dyspnea.  A  phase  II  study  is  now  underway
o  determine  the  pharmacokinetic  and  pharmacodynamic
roﬁles  of  two  doses  of  ticagrelor  plus  low-dose  aspirin  in
apanese  and  Asian  patients  with  stable  CHD  (clinicaltri-
ls.gov  registration  number:  NCT01118325).  The  results  of
his  study  are  eagerly  awaited  to  determine  the  relative
fﬁcacy  of  ticagrelor  in  this  patient  population.
hienopyridines and liver dysfunction
oth  clopidogrel  and  ticlopidine  have  been  associated  with
epatotoxicity,  such  as  hepatitis  and  cholestatic  jaundice.
hese  associations  have  been  reported  in  case  reports
72—74]  and  as  adverse  events  in  clinical  trials  [24,75], and
he  rates  of  these  events  seem  to  be  higher  in  Asian  patients
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han  in  Western  patients  [76]. The  reason  for  this  is  unclear,
ut  it  has  been  suggested  to  be  related  to  human  leuko-
yte  antigen  genomic  subtypes  [77]. At  this  stage,  it  is  not
ossible  to  determine  whether  hepatotoxicity  is  a  cause  for
oncern  with  the  newer  thienopyridines,  as  no  data  have
een  reported  in  this  setting.  Nevertheless,  clinicians  should
e  aware  of  the  possibility  of  hepatotoxicity  when  treating
atients  with  these  drugs.
ummary and future prospects
lopidogrel  is  the  antiplatelet  drug  of  choice  for  use
n  combination  with  aspirin  to  prevent  atherothrombotic
vents  in  patients  with  ACS  undergoing  PCI.  However,  some
atients  remain  at  increased  risk  of  subsequent  cardiovas-
ular  events  despite  treatment  with  clopidogrel.  As  such,
ovel  agents  that  provide  further  risk  reductions  for  car-
iovascular  events  are  required.  Prasugrel  and  ticagrelor
re  antiplatelet  agents  that  have  shown  promise  in  clin-
cal  trials.  Prasugrel  is  already  approved  for  use  in  the
revention  of  thrombotic  cardiovascular  events  in  patients
ith  ACS  undergoing  PCI,  and  ticagrelor  is  in  preregistra-
ion  for  a  similar  indication  in  patients  with  ACS.  Both  drugs
re  under  development  in  Japan,  and  a  new  indication  for
rasugrel  is  currently  being  explored.  Because  ethnic  differ-
nces  in  cardiovascular  risk  factors  exist  (e.g.  lipid  control,
bdominal/visceral  obesity,  insulin  resistance),  and  because
apanese  guidelines  on  the  prevention  of  cardiovascular  dis-
ase  are  largely  based  on  studies  in  European  populations,
arge  cardiovascular  prevention  studies  in  Japanese  patients
ith  carefully  titrated  doses  are  essential,  as  are  studies
o  assess  the  safety  and  efﬁcacy  of  the  newer  agents  such
s  prasugrel  and  ticagrelor.  This  is  particularly  important
onsidering  the  studies  showing  more  effective  inhibition  of
latelet  aggregation  in  phase  II  studies  of  prasugrel  in  Asian
han  in  white/Caucasian  populations  [69,70].  Japanese-
peciﬁc  guidelines  based  on  ﬁndings  from  such  studies  are
reatly  anticipated.
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